Cyclophosphamide and paclitaxel as initial or salvage regimen for the mobilization of peripheral blood progenitor cells

Bone Marrow Transplantation

Volumn 24, Issue 9, 1999, Pages 959-963

  Klein, J L ^a   Rey, P M ^a   Dansey, R ^a   Karanes, C ^a   Abella, E ^a   Cassells, L ^a   Hamm, C ^a   Flowers, M ^a   Couwlier, C ^a   Peters, W P ^a   Baynes, R D ^a  

^a KARMANOS CANCER INSTITUTE   (United States)

Author keywords

CD34 selection; Isolex 300i; Mobilization; PBPC

Indexed keywords

CARMUSTINE; CD34 ANTIGEN; CISPLATIN; CYCLOPHOSPHAMIDE; DACARBAZINE; IFOSFAMIDE; MELPHALAN; PACLITAXEL; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; AGED; APHERESIS; ARTICLE; BONE MARROW SUPPRESSION; BREAST CANCER; BRONCHITIS; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CATHETER INFECTION; CELL TRANSPLANTATION; DRUG SAFETY; FEBRILE NEUTROPENIA; FEMALE; FLUORESCENCE ACTIVATED CELL SORTER; HUMAN; MULTIMODALITY CANCER THERAPY; PRIORITY JOURNAL; SINUSITIS; STEM CELL;

EID: 0032760471     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1702009     Document Type: Article

References (27)

1. Henon R, Liang H, Beck-Wirth G et al. Comparison of hematopoietic and immune recovery after autologous bone marrow or blood stem cell transplants. Bone Marrow Transplant 1992; 9: 285-291.
2. To LB, Roberts MM, Haylock DN et al. Comparison of haematological recovery times and supportive care requirements of autologous recovery phase peripheral blood stem cell transplants, autologous bone marrow transplants and allogeneic bone marrow transplants. Bone Marrow Transplant 1992; 9: 277-284.
3. Lopez M, Mortel O, Pouillart P et al. Acceleration of hematopoietic recovery after autologous bone marrow transplantation by low doses of peripheral blood stem cells. Bone Marrow Transplant 1991; 7: 173-181.
4. Peters WP, Rosner G, Ross M et al. Comparative effects of GM-CSF and G-CSF on priming peripheral blood progenitor cells for use with autologous bone marrow after high dose chemotherapy. Blood 1993; 81: 1709-1719.
5. Bensinger W, Appelbaum F, Rowley S et al. Factors that influence collection and engraftment of autologous peripheral-blood stem cells. J Clin Oncol 1995; 13: 2547-2555.
6. Alegre A, Tomas JF, Martinez-Chamorro C et al. Comparison of peripheral blood progenitor cell mobilization in patients with multiple myeloma: high-dose cyclophophamide plus GM-CSF vs G-CSF alone. Bone Marrow Transplant 1997; 20: 211-217.
7. Venturini M, DelMartro L, Melioli G. Release of peripheral blood progenitor cells during standard dose cyclophosphamide, epidoxorubicin, 5-fluorouracil regimen plus granulocyte colony stimulating factor for breast cancer therapy. Cancer 1994; 74: 2300-2306.
8. Olivieri A, Offidani M, Ciniero L et al. DHAP regimen plus G-CSF as salvage therapy and priming for blood progenitor cell collection in patients with poor prognosis lymphoma. Bone Marrow Transplant 1995; 16: 85-93.
9. Demirer T, Rowley S, Buckner CD et al. Peripheral-blood stem-cell collections after paclitaxel, cyclophosphamide, and recombinant human granulocyte colony-stimulating factor in patients with breast and ovarian cancer. J Clin Oncol 1995; 13: 1714-1719.
10. Weaver CH, Schwartzberg LS, Birch R et al. Collection of peripheral blood stem cells following administration of paclitaxel, cyclophosphamide and G-CSF in patients with breast and ovarian cancer. Biol Blood Marrow Transplant 1997; 3: 83-90.
11. Bensinger WI, Longin K, Appelbaum F et al. Peripheral blood stem cells collected after recombinant granulocyte colony stimulating factor: an analysis of factors correlating with the tempo of engraftment after transplantation. Br J Haematol 1994; 87: 825-831.
12. Haas R, Möhle R, Früehauf S. Patient characteristics associated with successful mobilizing and autografting of peripheral blood progenitor cells in malignant lymphoma. Blood 1994; 83: 3787-3794.
13. Kotasek D, Shepherd KM, Sage RE et al. Factors affecting blood stem cell collections following high-dose cyclophosphamide mobilization in lymphoma, myeloma and solid tumors. Bone Marrow Transplant 1992; 9: 11-17.
14. Schwartzberg LS, Birch R, Hazelten B et al. Peripheral blood stem cell mobilization by chemotherapy with and without rh-filgrastim. J Hematother 1992; 1: 317-327.
15. Weaver CH, Hazelton B, Birch R et al. An analysis of engraftment kinetics as a function of the CD34 content of peripheral blood progenitor cell collections in 692 patients after the administration of myeloablative chemotherapy. Blood 1995; 86: 3961-3969.
16. Weaver CH, Tauer K, Zhen B et al. Second attempts at mobilization of peripheral blood stem cells in patients with initial low CD34+ cell yields. J Hematother 1998; 7: 241-249.
17. Sutherland DR, Anderson L, Keeney M et al. The ISHAGE guidelines for CD34+ cell determination by flow cytometry. J Hematother 1996; 5: 213-226.
18. Seidman AD, Crown JPA, Reichman B et al. Lack of clinical cross resistance of paclitaxel with anthracycline in the treatment of metastatic breast cancer. Proc Am Soc Clin Oncol 1993; 12: 63 (Abstr. 53).
19. Shea TC. Mobilization of peripheral blood progenitor cells with paclitaxel-based chemotherapy. Semin Oncol 1997; 107 (Suppl. 2): 105-107.
20. Holmberg LA, Demirer T, Rowley S et al. High-dose busulfan, melphalan and thiotepa followed by autologous peripheral blood stem cell (PBSC) rescue in patients with advanced stage III/IV ovarian cancer. Bone Marrow Transplant 1998; 22: 651-659.
21. Raptis G, Tiersten A, Fennelly D et al. The addition of paclitaxel to high dose cyclophosphamide + G-CSF markedly enhances the mobilization of CD34+ peripheral blood progenitor cells in patients with responding metastatic breast cancer undergoing high dose chemotherapy. Proc Am Soc Clin Oncol 1995; 14: 313 (Abstr.).
22. Pedrazzoli P, Perotti C, Da Prada GA et al. Collection of circulating progenitor cells after epirubicin, paclitaxel and G-CSF in patients with metastatic breast cancer. Br J Cancer 1997; 75: 1368-1372.
23. Demirer T, Buckner D, Storer B et al. Effect of different chemotherapy regimens on peripheral-blood stem-cell collections in patients with breast cancer receiving granulocyte colony-stimulating factor. J Clin Oncol 1997; 15: 684-690.
24. Conte PF, Gennari A, Salvadori B et al. Paclitaxel plus epirubicin in advanced breast cancer. Oncology 1998; 12 (Suppl. 1): 40-44.
25. Bengala C, Pazzagli I, Tibaldi C et al. Mobilization, collection, and characterization of peripheral blood hemopoietic progenitors after chemotherapy with epirubicin, paclitaxel, and granulocyte-colony stimulating factors administered to patients with metastatic breast carcinoma. Cancer 1998; 82: 867-873.
26. Watts MJ, Sullivan AM, Jamieson E et al. Progenitor-cell mobilization after low-dose cyclophosphamide and granulocyte colony-stimulating factor: an analysis of progenitor-cell quantity and quality and factors predicting for these parameters in 101 pretreated patients with malignant lymphoma. J Clin Oncol 1997; 15: 535-546.
27. Pecora AL, Preti RA, Gleim GW et al. CD34+CD33- cells influence days to engraftment and transfusion requirements in autologous blood stem-cell recipients. J Clin Oncol 1998; 16: 2093-2104.